article · Archives of Biological Sciences
Tuberculosis is a global public health concern, and its treatment is frequently associated with hepatotoxic side effects. Phytotherapy represents a promising complementary approach. This study aimed to characterize the phenolic profile of the n-butanol extract of Crotalaria vialattei (BCV), evaluate its antioxidant capacity, and assess its hepatoprotective effects against liver damage induced by a fixed-dose antituberculosis drug combination containing rifampin, isoniazid, and pyrazinamide (RHZ). Phytochemical analysis revealed a phenolic-rich extract, identifying 17 polyphenolic compounds. BCV exhibited measurable antioxidant activity in vitro. In vivo, oral administration of RHZ (rifampin 150 mg/kg, isoniazid 75 mg/kg, and pyrazinamide 400 mg/kg) induced marked alterations in hepatic biochemical markers, lipid profile, oxidative status, and liver histoarchitecture. BCV treatment significantly attenuated these changes by improving liver enzyme activities, restoring oxidative balance, and preserving liver architecture. Overall, the BCV extract demonstrates antioxidant-associated hepatoprotective potential against RHZ-induced liver injury and may represent a promising complementary strategy to reduce antituberculosis drug-related hepatotoxicity.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.2298/abs260110001z
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.